In summary, LCAT deficiency in hamsters promotes liver lipid deposition and MASH progression, thus highlighting the therapeutic role of LCAT in MASLD and MASH. The gene discussed is LCAT; the disease is metabolic dysfunction-associated steatotic liver disease.